Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis
- 125 Downloads
The aim of the study is to investigate the levels of serum interleukin-35 (IL-35) before and after treatment and its relationship with clinical parameters as well as the frequency of different subsets of CD4+ T cells in patients with systemic sclerosis (SSc) to explore the role of IL-35 in the pathogenesis of SSc. The levels of serum IL-35, interferon-γ (IFN-γ), IL-4, IL-17A, and IL-10 in 49 patients with SSc and 50 age- and gender-matched healthy subjects were measured by enzyme-linked immunosorbent assay (ELISA). The percentages of peripheral blood Th1, Th2, Th17 cells and Tregs in 49 SSc patients and 20 healthy controls were characterized by flow cytometry. The relationship between the levels of serum IL-35 and the percentages of different subsets of CD4+ T cells, disease duration, the values of forced vital capacity (FVC), modified Rodnan skin scores (MRSS) or high-resolution computed tomography (HRCT) scores was analyzed in patients with SSc. The levels of serum IL-35 in SSc patients were significantly higher than that of healthy controls (P < 0.001), but significantly reduced after treatment for 3 months (P = 0.001). The levels of serum IL-35 were positively correlated with the HRCT scores in SSc patients (P = 0.014) and with disease duration in patients with diffuse cutaneous SSc (P = 0.03), but negatively correlated with the FVC values in SSc patients (P = 0.034). In comparison with that in the healthy controls, significantly decreased percentages of Th1, but increased Th2 and Th17 cells were detected in patients, leading to reduced ratios of Th1/Th2 and increased ratios of Th17/Tregs (P < 0.001). The levels of serum IL-35 were positively correlated with IL-4 (P = 0.036) and tended to be positively associated with the frequency of Tregs in SSc patients (P = 0.054). Higher levels of serum IL-35 may be associated with the development of SSc and severity of pulmonary fibrosis in SSc patients.
KeywordsInterleukin-35 Different subsets of CD4+ T cells Interleukin-4 Systemic sclerosis
The authors would like to express their appreciation to Professor Jia-Quan Li, Guangxi Medical University, for his assistance and advice in performing experiments. This manuscript has been edited and proofread by Medjaden Bioscience Limited.
Jie Tang carried out the experiments, data collection and interpretation and writing the manuscript. Ling Lei designed the study, analyzed and interpreted the data, reviewed the manuscript, and supervised the entire study. Jie Pan helped to perform experiments and data acquisition. Cheng Zhao and Jing Wen participated in data collection and analysis. All authors read and approved the final manuscript.
This study was supported by grants from the Guangxi Natural Science Foundation (Grant No. 2016GXNSFAA380175).
Compliance with ethical standards
This study was approved by the Ethical Committee of the First Affiliated Hospital of GuangXi Medical University. Written informed consent was obtained from all patients and healthy controls.
Conflict of interest
All authors have no conflict of interest to declare. There is no any interest or relationship with pharmaceutical agencies within the past 36 months.
- 11.van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Cordiali-Fei P, Mussi A, D'Agosto G, Trento E, Bordignon V, Trincone S, Vento A, Sperduti I, Cristaudo A, Ensoli F (2013) Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol 2013:390563CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Lei L, Zhao C, Qin F, He ZY, Wang X, Zhong XN (2016) Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol 100(5):14–22Google Scholar
- 22.Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martinez-Reyes C, Díaz-Zamudio M, Llorente L (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32(9):2653–2660CrossRefPubMedGoogle Scholar